Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAVs and Dendritic Cells for Aggressive Leukemias
NCT05321940Phase 1Withdrawn
- Start
- Nov 2023
- Primary completion
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Cell Therapies, Vaccines & Immunotherapeutics
01
Overview
Phase 1, open-label, single-arm trial of staphylococcal enterotoxins + autologous leukemic cells in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and adult T-cell leukemia-lymphoma (ATLL). Primary endpoint: Incidence of Treatment-Related Adverse Events up to 12 months. Planned start Nov 2023; status: withdrawn.
02
Drugs
staphylococcal enterotoxins + autologous leukemic cells
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on NCT05321940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05321940.